| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Daniel Ford maintains Sempra (NYSE:SRE) with a Neutral and raises the price target from $82 to $98.
Barclays analyst Nicholas Campanella maintains Sempra (NYSE:SRE) with a Overweight and lowers the price target from $101 to ...
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...
Earnings GuidanceSempra is updating its full-year 2025 GAAP earnings-per-common-share (EPS) guidance range of $3.05 to $3.45, r...
Mad Money Lightning Round: Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE...
Wells Fargo analyst Shahriar Pourreza initiates coverage on Sempra (NYSE:SRE) with a Overweight rating and announces Price T...